Trial Profile
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs TRC 253 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors TRACON Pharmaceuticals
- 29 Mar 2021 Study design changed from open to sequential.
- 14 Dec 2020 Status changed from active, no longer recruiting to completed.
- 08 Oct 2020 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.